Jazz Pharma Says New Data on JZP-110 Showed Each Doses Had Consistently Lower Ratings on Primary Endpoint of Peak Liking at the Moment, Secondary Endpoints of Overall Drug Liking, Willingness to Take
Paul Quintaro